048530 — iNtRON Biotechnology Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩209bn
- KR₩152bn
- KR₩10bn
- 53
- 14
- 36
- 22
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 69,568 | 66,169 | 83,497 | 47,351 | 57,184 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,953 | 12,207 | 40,641 | 65,268 | 2,697 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 75,287 | 81,327 | 125,513 | 113,928 | 60,980 |
Net Property, Plant And Equipment | 7,550 | 11,951 | 13,758 | 15,031 | 22,696 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 89,032 | 100,536 | 153,365 | 140,959 | 98,615 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,675 | 12,704 | 33,254 | 32,218 | 786 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 24,068 | 15,157 | 52,016 | 34,777 | 1,880 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 64,964 | 85,379 | 101,349 | 106,181 | 96,734 |
Total Liabilities & Shareholders' Equity | 89,032 | 100,536 | 153,365 | 140,959 | 98,615 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |